Cargando…

Pembrolizumab plus pemetrexed-carboplatin combination in first-line treatment of advanced non-squamous non-small cell lung cancer: a multicenter real-life study (CAP29)

BACKGROUND: Pembrolizumab combined with chemotherapy is now first-line standard of care in advanced non-small cell lung cancer. This real-life study aimed to assess efficacy and safety of carboplatin-pemetrexed plus pembrolizumab in advanced non-squamous non-small cell lung cancer. METHODS: CAP29 is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Renaud, Emmanuelle, Ricordel, Charles, Corre, Romain, Leveiller, Guillaume, Gadby, Florence, Babey, Hélène, Annic, Josselin, Lucia, François, Bourbonne, Vincent, Robinet, Gilles, Descourt, Renaud, Orione, Charles, Quéré, Gilles, Geier, Margaux
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989798/ https://www.ncbi.nlm.nih.gov/pubmed/36895931 http://dx.doi.org/10.21037/tlcr-22-556

Ejemplares similares

Real‐life second‐line epirubicin–paclitaxel regimen as treatment of relapsed small‐cell lung cancer: EpiTax study
por: Annic, Josselin, et al.
Publicado: (2022)

First‐line pembrolizumab for non–small cell lung cancer patients with PD‐L1 ≥50% in a multicenter real‐life cohort: The PEMBREIZH study
por: Amrane, Karim, et al.
Publicado: (2020)

Vascular Acrosyndromes Associated With Prolonged Tumor Response in Advanced Lung Cancer Patients During Treatment With Antimetabolites: A Report of Two Cases
por: Geier, Margaux, et al.
Publicado: (2021)

Duration of nivolumab for pretreated, advanced non–small‐cell lung cancer
por: Geier, Margaux, et al.
Publicado: (2020)

Brief Report on the Efficacy of Nivolumab in Patients With Previously Treated Advanced Large-Cell Neuroendocrine Cancer of the Lung
por: Agar, Camille, et al.
Publicado: (2020)

Henoch–Schönlein Purpura Associated with Lung Cancer: When Paraneoplastic Manifestations Impede Oncological Management
por: Philippe, Éloïse, et al.
Publicado: (2021)

Durvalumab‐induced lesions of bronchiolitis and fully reversible bronchiectasis in a patient with non‐small cell lung cancer: A case report
por: Domblides, Maël, et al.
Publicado: (2021)

Carboplatin/pembrolizumab/pemetrexed: COVID-19 pneumonia: case report
Publicado: (2021)

Phase III randomized study of carboplatin pemetrexed with or without bevacizumab with initial versus “at progression” cerebral radiotherapy in advanced non squamous non-small cell lung cancer with asymptomatic brain metastasis
por: Monnet, Isabelle, et al.
Publicado: (2021)

Mutational status of synchronous and metachronous tumor samples in patients with metastatic non-small-cell lung cancer
por: Quéré, Gilles, et al.
Publicado: (2016)

Prospective, multicentre, single-arm phase II trial of pembrolizumab combined with carboplatin and pemetrexed in elderly patients with advanced, non-squamous non-small cell lung cancer
por: Ozawa, Yuichi, et al.
Publicado: (2020)

Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices
por: Velcheti, Vamsidhar, et al.
Publicado: (2021)

Phase II study of carboplatin, pemetrexed, and bevacizumab in advanced nonsquamous non–small‐cell lung cancer
por: Laslett, Nicole F., et al.
Publicado: (2018)

Multi-Omics Approaches for the Prediction of Clinical Endpoints after Immunotherapy in Non-Small Cell Lung Cancer: A Comprehensive Review
por: Bourbonne, Vincent, et al.
Publicado: (2022)

Case Report: Coronaro-bronchial fistula vascularizing a squamous cell lung cancer
por: Ntshaykolo, Chloe, et al.
Publicado: (2023)

Phase II study of pemetrexed and carboplatin plus bevacizumab, followed by maintenance pemetrexed and bevacizumab in Japanese patients with non-squamous non-small cell lung cancer
por: YOKOI, TAKASHI, et al.
Publicado: (2014)

Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression
por: Cardona, Andrés Felipe, et al.
Publicado: (2016)

Carboplatin, pemetrexed, and pembrolizumab was effective for primary salivary gland‐type lung adenocarcinoma diagnosed due to esophageal stricture: A case report
por: Kawakado, Keita, et al.
Publicado: (2021)

Efficacy and safety of first-line pemetrexed plus carboplatin followed by single-agent pemetrexed maintenance in elderly Chinese patients with non-squamous non-small-cell lung cancer
por: Zhao, Xinmin, et al.
Publicado: (2017)

Carboplatin/pemetrexed: COVID-19 infection: 2 case reports
Publicado: (2021)

Successful Treatment with Pemetrexed, Carboplatin, and Bevacizumab for Platinum-Resistant Adenocarcinoma of the Lung
por: Wada, Sae, et al.
Publicado: (2012)

Sinus arrhythmia caused by pemetrexed with carboplatin combination: A case report
por: Quan, Xianghua, et al.
Publicado: (2022)

Pemetrexed plus cisplatin/carboplatin in previously treated locally advanced or metastatic non-small cell lung cancer patients
por: Zhang, Guan-Zhong, et al.
Publicado: (2010)

65Plus: open-label study of bevacizumab in combination with pemetrexed or pemetrexed/carboplatin as first-line treatment of patients with advanced or recurrent nonsquamous non-small-cell lung cancer
por: Schuette, Wolfgang, et al.
Publicado: (2017)

PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non–Small-Cell Lung Cancer
por: Zinner, Ralph G., et al.
Publicado: (2015)

Narrative Review of Synergistics Effects of Combining Immunotherapy and Stereotactic Radiation Therapy
por: Lucia, François, et al.
Publicado: (2022)

Evaluation of calculating carboplatin dosage in carboplatin–pemetrexed therapy as the first‐line therapy for Chinese patients with advanced lung adenocarcinoma
por: Zhu, Yixiang, et al.
Publicado: (2018)

Slowly developing toxic epidermal necrolysis-like reaction associated with pemetrexed and carboplatin
por: Eichhoff, Gerhard
Publicado: (2020)

Phase i study of 'dose-dense' pemetrexed plus carboplatin/radiotherapy for locally advanced non-small cell lung carcinoma
por: Shen, Xinglei, et al.
Publicado: (2011)

Acute cerebral arterial embolism following pemetrexed and carboplatin treatment in non-small-cell lung cancer: A case report
por: TAKEDA, MASAYUKI, et al.
Publicado: (2013)

Hospitalization and Survival of Medicare Patients Treated With Carboplatin Plus Paclitaxel or Pemetrexed for Metastatic, Nonsquamous, Non–Small Cell Lung Cancer
por: Brooks, Gabriel A., et al.
Publicado: (2018)

Pembrolizumab plus pemetrexed‐platinum for metastatic nonsquamous non–small‐cell lung cancer: KEYNOTE‐189 Japan Study
por: Horinouchi, Hidehito, et al.
Publicado: (2021)

Synchronous lung and gastric cancers successfully treated with carboplatin and pemetrexed: a case report
por: Sato, Takashi, et al.
Publicado: (2012)

Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
por: Patil, Vijay Maruti, et al.
Publicado: (2017)

Toxicity after volumetric modulated arc therapy for lung cancer: a monocentric retrospective study
por: Bourbonne, Vincent, et al.
Publicado: (2021)

Focus on treatment of lung carcinoid tumor
por: Noel-Savina, Elise, et al.
Publicado: (2013)

Elderly Subset Analysis of Randomized Phase III Study Comparing Pemetrexed Plus Carboplatin with Docetaxel Plus Carboplatin as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer
por: Pereira, José Rodrigues, et al.
Publicado: (2013)

Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysis
por: Hayashi, Toshinobu, et al.
Publicado: (2021)

Using the neutrophil‐to‐lymphocyte ratio to predict the outcome of individuals with nonsquamous non‐small cell lung cancer receiving pembrolizumab plus platinum and pemetrexed
por: Imai, Hisao, et al.
Publicado: (2023)

Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma
por: Ceresoli, G L, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_3kqsbsc3taq5ihs8v9nl00n7mr